INVESTIGATION OF THE CLINICAL SIGNIFICANCE OF ESCITALOPRAM-INDUCED ELECTROCARDIOGRAPHIC CHANGES IN MEN: A PILOT OBSERVATIONAL STUDY
Objective: We sought to investigate the clinical significance of secondary electrocardiographic (ECG) changes in men after using escitalopram.
Methods: This pilot observational cohort study recruited male patients taking escitalopram for at least 6 mo in Mental Hospital of Qassim. All patients underwent a 12-lead ECG examination. We also measured the heart rate (HR), QTc, and QRS interval. Data on all related medical conditions and medications were recorded.
Results: Fifty-three men were recruited, with a mean age of 37.39±8.39 y: 34.4% and 31.1% of these patients were taking escitalopram for depression and anxiety, respectively. The mean dose of escitalopram was 14.35 mg. Observations showed that 20.9% of the patients taking escitalopram had a fast HR (>100 beats/min [bpm]), indicative of sinus tachycardia, whereas 11.4% of patients had a slow HR (<60 bpm). The mean QT and QTc in patients taking escitalopram were 366.62±28.69 and 398.92±16.15 ms, respectively.
Conclusion: Low doses of escitalopram resulted in minimal clinically significant changes. Thus, patients should be monitored when doses are escalated further.
2. US Food Drug Administration. Lexapro tablet; 2004. Available from: https://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-22-tab11C-Lexapro-Tabs-SLR015.pdf. [Last accessed on 14 Mar 2018]
3. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007;46:281-90.
4. US Food Drug Administration (FDA). Clinical Evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Silver spring: center for drug evaluation and research and center for biologics evaluation and research; 2005. p. E14.
5. Yuksel FV, Tuzer V, Goka E. Escitalopram intoxication. Eur Psychiatry 2005;20:82.
6. Van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009;54:404-8.
7. Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 2 d associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review. Gen Hosp Psychiatry 2012;34:210. e13-5.
8. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013;47:1330-41.
9. U. S. Food and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses; 2012. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. [Last accessed on 10 Sep 2012]
10. Howland RH. A question about the potential cardiac toxicity of escitalopram. J Psychosoc Nurs Ment Health Serv 2012;50:17-20.
11. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014;75:e441-9.
12. Keller DL. Prescribe escitalopram instead of citalopram. Am J Med 2013;126:e21.
13. Scharko AM, Schumacher J. Prolonged QTc interval in a 14 y old girl with escitalopram overdose. J Child Adolesc Psychopharmacol 2008;18:297-8.
14. Medicines and Healthcare products Regulatory Agency. Citalopram and escitalopram: QT interval prolongation-new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Drug Safety 2011;5:A1.
15. Snitker S, Doerfler RM, Soliman EZ, Deor R, St Peter WL, Kramlik S, et al. Association of QT-prolonging medication use in CKD with electrocardiographic manifestations. Clin J Am Soc Nephrol 2017;9:pii: CJN.12991216.
16. Maljuric MN, Noordam R, Aarts N, Niemeijer MN, Van den Berg ME, Hofman A, et al. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based rotterdam study. Br J Clin Pharmacol 2015;80:698-705.
17. Carceller Sindreu M, de Diego Adelino J, Portella MJ, Garvia Moll X, Figueras M, Fernandez Vidal A, et al. Lack of relationship between plasma levels of escitalopram and QTc-interval length. Eur Arch Psychiatry Clin Neurosci 2017;267:815-22.
18. Hasnain M, Howland RH, Vieweg WV. Escitalopram and QTc prolongation. J Psychiatry Neurosci 2013;38:E11.
19. Chattar KB, Karve AA, Subramanyam AA, Tondare SB. Prescription pattern analysis of antidepressants in psychiatric outpatient department of tertiary care hospital in India. Asian J Pharm Clin Res 2016;9:77-9.
20. Mishra S, Swain T, Mohanty M. Patterns of prescription and efficacy evaluation of antidepressants in a tertiary care teaching hospital in Eastern India. Asian J Pharm Clin Res 2012;5:193-6.
21. Wozniak G, Toska A, Saridi M, Mouzas O. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit 2011;17:RA205-14.
22. Angermann CE, Gelbrich G, Stork S, Fallgatter A, Deckert J, Faller H, et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 2007;9:1212-22.
23. Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol 2013;23:1391-400.
24. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007;29:2319-32.
25. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008;118:434-42.
26. Schreffler SM, Marraffa JM, Stork CM, Mackey J. Sodium channel blockade with QRS widening after an escitalopram overdose. Pediatr Emerg Care 2013;29:998-1001.
27. Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics 2015;56:36-43.